Innate Pharma SA (IPHA) — SEC Filings

Overview

Innate Pharma SA (IPHA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 23, 2026: Innate Pharma SA filed a 6-K report on April 23, 2026. The filing includes a document titled 'EX-99.1' and a complete submission text file. The company's mailing and business address is in Marseille, France.

Sentiment Summary

Across 9 filings, the sentiment breakdown is: 1 bearish, 8 neutral. The dominant filing sentiment for Innate Pharma SA is neutral.

Filing Type Overview

Innate Pharma SA (IPHA) has filed 8 6-K, 1 20-F with the SEC between Mar 2026 to Apr 2026.

Recent Filings (9)

• Innate Pharma Files 6-K Report — 6-K · Apr 23, 2026 Risk: low
  Innate Pharma SA filed a 6-K report on April 23, 2026. The filing includes a document titled 'EX-99.1' and a complete submission text file. The company's mailin
• 6-K Filing — 6-K · Apr 17, 2026
• Innate Pharma Files 6-K Report — 6-K · Apr 13, 2026 Risk: low
  Innate Pharma SA filed a 6-K report on April 13, 2026. The filing includes a document labeled EX-99.1, which is an exhibit to the report. The company is based i
• Innate Pharma Files 6-K Report — 6-K · Apr 13, 2026 Risk: low
  Innate Pharma SA filed a 6-K report on April 13, 2026. The filing includes a 6-K document and an exhibit (EX-99.1). The company's mailing and business address i
• Innate Pharma Files 6-K Report — 6-K · Apr 8, 2026 Risk: low
  Innate Pharma SA filed a Form 6-K on April 8, 2026. This report is for a foreign issuer and includes documents such as the 6-K itself and Exhibit 99.1. The fili
• 6-K Filing — 6-K · Apr 3, 2026
• Innate Pharma Files 6-K Report — 6-K · Apr 2, 2026 Risk: low
  Innate Pharma SA filed a 6-K report on April 2, 2026. The filing includes exhibit EX-99.1 and a complete submission text file. The company's mailing and busines
• Innate Pharma Faces High R&D Uncertainty, Relies on Partnerships — 20-F · Apr 1, 2026 Risk: high
  Innate Pharma SA (IPHA) filed its 20-F for the fiscal year ended December 31, 2025, highlighting its status as a clinical-stage oncology-focused biotech company
• Innate Pharma Files Routine 6-K Report on March 26, 2026 — 6-K · Mar 26, 2026
  Innate Pharma SA filed a 6-K report on March 26, 2026, indicating a routine foreign issuer report. This filing, with accession number 0001628280-26-021168, incl

Risk Profile

Risk Assessment: Of IPHA's 6 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 5 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Jonathan Dickinson

Industry Context

The oncology drug development landscape is intensely competitive, characterized by rapid scientific advancements and significant investment. Companies like Innate Pharma operate in a high-risk, high-reward environment, focusing on novel mechanisms of action to address unmet medical needs. The industry trend is towards personalized medicine and combination therapies, requiring substantial R&D expenditure and strategic partnerships.

Top Tags

foreign-issuer (5) · regulatory-filing (5) · corporate-update (1) · sec-filing (1) · regulatory-update (1) · Biotechnology (1) · Oncology (1) · Clinical Stage (1) · R&D Risk (1) · Partnerships (1)

Key Numbers

• 6-K document size: 8488 — Indicates the size of the primary 6-K filing document.
• EX-99.1 document size: 12855 — Indicates the size of the exhibit document.
• Ordinary shares outstanding: 93,719,323 — As of December 31, 2025, indicating the current share count.
• Nominal value per ordinary share: 0.05 — The stated value of each ordinary share.

Related Companies

AZN · SNY

Frequently Asked Questions